Theoretical insights into the encapsulation of anticancer Oxaliplatin drug into single walled carbon nanotubes

被引:0
作者
Rezvani, Mahyar [1 ]
Ahmadnezhad, Iran [2 ]
Ganji, Masoud Darvish [3 ]
Fotukian, Maria [4 ]
机构
[1] Islamic Azad Univ, Arak Branch, Dept Chem, Arak, Iran
[2] Islamic Azad Univ, Babol Branch, Dept Chem, Babol Sar, Iran
[3] Islamic Azad Univ, Pharmaceut Sci Branch, Fac Pharmaceut Chem, Dept Nanochem, Tehran, Iran
[4] Islamic Azad Univ, Qaemshahr Branch, Dept Chem, Qaemshahr, Iran
来源
JOURNAL OF NANOANALYSIS | 2016年 / 3卷 / 03期
关键词
SWCNTs; Drug delivery; ab initio calculations; oxaliplatin; vdW-DF; Cancer drugs;
D O I
暂无
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
The present work was an attempt to evaluate the potentialities of using SWCNTs as nanovectors for drug delivery of anticancer drug Oxaliplatin. First-principles van der Waals density functional (vdW-DF) calculations are used to investigate the incorporation of oxaliplatin inside the typical semiconducting and metallic single wall carbon nanotubes with various diameters (SWCNTs). Adsorption energy is calculated and the results show that oxaliplatin affinity for the semiconducting SWCNTs is stronger than that for the metallic counterparts. The obtained binding energies reveal that oxaliplatin prefers to be encapsulated into the semiconducting and metallic nanotubes with diameter of about 9 and 11 angstrom, respectively. We also found that vdW forces mainly contribute to the binding of selected drug molecule to SWCNTs. The study of the electronic structures and charge analysis indicate that no significant hybridization between the respective orbital takes place and the small interaction obtained quantitatively in terms of binding energies. Our findings afford not only a molecular insight into understanding of the interaction between oxaliplatin and SWCNTs but also may be instructive to relevant scientists who are attempt to develop effective methods for suitable nanovectors for drug delivery.
引用
收藏
页码:69 / 75
页数:7
相关论文
共 49 条
  • [1] Effect of functional groups at hole edges on cisplatin release from inside single-wall carbon nanohorns
    Ajima, K
    Yudasaka, M
    Maigné, A
    Miyawaki, J
    Iijima, S
    [J]. JOURNAL OF PHYSICAL CHEMISTRY B, 2006, 110 (11) : 5773 - 5778
  • [2] Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen
    André, T
    Bensmaine, MA
    Louvet, C
    François, E
    Lucas, V
    Desseigne, F
    Beerblock, K
    Bouché, O
    Carola, E
    Merrouche, Y
    Morvan, F
    Dupon-André, G
    de Gramont, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (11) : 3560 - 3568
  • [3] Balakumar K., 2012, INT J NANOMATER BIOS, V4, P55
  • [4] Targeted Killing of Cancer Cells in Vivo and in Vitro with EGF-Directed Carbon Nanotube-Based Drug Delivery
    Bhirde, Ashwin A.
    Patel, Vyomesh
    Gavard, Julie
    Zhang, Guofeng
    Sousa, Alioscka A.
    Masedunskas, Andrius
    Leapman, Richard D.
    Weigert, Roberto
    Gutkind, J. Silvio
    Rusling, James F.
    [J]. ACS NANO, 2009, 3 (02) : 307 - 316
  • [5] Can carbon nanotubes be considered useful tools for biological applications?
    Bianco, A
    Prato, M
    [J]. ADVANCED MATERIALS, 2003, 15 (20) : 1765 - 1768
  • [6] Applications of carbon nanotubes in drug delivery
    Bianco, A
    Kostarelos, K
    Prato, M
    [J]. CURRENT OPINION IN CHEMICAL BIOLOGY, 2005, 9 (06) : 674 - 679
  • [7] Role of Dihydrogen Bonds for the Stabilization of Self-Assembled Molecular Nanostructures
    Blankenburg, S.
    Rauls, E.
    Schmidt, W. G.
    [J]. JOURNAL OF PHYSICAL CHEMISTRY C, 2009, 113 (29) : 12653 - 12657
  • [8] Cottu P. H., 2000, P AN M AM SOC CLIN, V19, P155
  • [9] Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
    de Gramont, A
    Figer, A
    Seymour, M
    Homerin, M
    Hmissi, A
    Cassidy, J
    Boni, C
    Cortes-Funes, H
    Cervantes, A
    Freyer, G
    Papamichael, D
    Le Bail, N
    Louvet, C
    Hendler, D
    de Braud, F
    Wilson, C
    Morvan, F
    Bonetti, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (16) : 2938 - 2947
  • [10] Phase II trial of oxaliplatin (L-OHP) in advanced, recurrent and/or metastatic squamous cell carcinoma of the head and neck
    Degardin, M
    Cappelaere, P
    Krakowski, I
    Fargeot, P
    Cupissol, D
    Brienza, S
    [J]. ORAL ONCOLOGY-EUROPEAN JOURNAL OF CANCER PART B, 1996, 32B (04): : 278 - 279